Please wait a minute...
93TMR Cancer  2019, Vol. 2 Issue (3): 216-221    DOI: 10.12032/TMRC201800055
Clinical Cancer Research     
The clinical efficacy analysis of radiofrequency ablation combined with chemotherapy in treating late non-small cell lung cancer
Ying-Ying Liu1, Feng Xu2,*()
1. Chengde Medical University, Chengde,067000, China
2. Department of Respiratory and critical Medicine, Cangzhou people°s Hospital, Cangzhou,061000,China.
Download: HTML     PDF(714KB)
Export: BibTeX | EndNote (RIS)      


CT-guided radiofrequency ablation combined with chemotherapy may be one effective method for the treatment of advanced non-small cell lung cancer (NSCLC).

Radiofrequency ablation is a precise treatment,which may improve disease control rate and the life quality of patients with NSCLC.


At present, the research on the combined treatment of NSCLC is still limited, and the treatment effect is not clear.At present, the therapeutic effect of combination therapy on NSCLC requires further clinical validation evidence. This article provides clinical evidence for the role of radiotherapy combined with chemotherapy in the treatment of advanced NSCLC.


Objective: To study the short-term efficacy and improvement effect on the quality of life of CT guided radiofrequency ablation(RFA) in treating late non-small cell lung cancer. Methods: 317 patients with non-small cell lung cancer (87 cases in the observation group and 230 cases in the control group) were selected for propensity score matching, with a matching tolerance of 0.05, and 42 pairs were successfully paired. The changes in chest enhanced CT before and 3 months after treatment and the quality of life measurement scale EORTC QLQ-C30 in Chinese version were evaluated. Results: The disease control rate of the observation group was 88.09%, which was significantly higher than that of the control group (61.91%). The functional and symptom scores of the two groups after treatment were significantly better than those before treatment, and the indicators of the observation group after treatment were better than those of the control group (P< 0.05). Conclusion: CT-guided radiofrequency ablation combined with chemotherapy is safe and effective in the treatment of NSCLC, which can control local tumor progression, reduce tumor burden, and improve the quality of life of patients with advanced NSCLC.

Key wordsCT guided      Radiofrequency ablation      Non-small cell lung cancer      QLQ-C30     
Received: 30 May 2019      Published: 17 August 2019
Fund:  Hebei Province Key R&D Program (1827778ID)
Corresponding Authors: Xu Feng   
Cite this article:

Ying-Ying Liu , Feng Xu . The clinical efficacy analysis of radiofrequency ablation combined with chemotherapy in treating late non-small cell lung cancer. 93TMR Cancer, 2019, 2(3): 216-221. doi: 10.12032/TMRC201800055

URL:     OR

Subjects Classification Experimental group(n = 42) Control group(n = 42) P
Age(x?s,year) 64.21 ± 9.19 64.83 ± 9.24 0.759
Gender 0.823
Male 16 17
Female 25 26
Pathological type 0.794
Adenocarcinoma 32 33
Squamous cell carcinoma 10 9
TNM stage 0.807
ⅢB stage 30 31
Ⅳ stage 12 11
Tumor diameter 0.807
≤ 3cm 30 31
>3cm 12 11
Table 1 Baseline comparison of two groups of patients
Experimental group(n=42) 11 14 12 5 37(88.09)
Control group(n=42) 7 9 11 15 27(64.29)
P <0.05
Table 2 Comparison of disease control rates between the two groups of patients/case (%)
Observation index Control group(n=42) Experimental group(n=42)
Before treatment After treatment Before treatment After treatment
Physical function 41.42±3.23 46±4.52* 41.54±3.74 55±3.97*#
Role function 40.26±4.32 45±4.94* 40.37±5.10 50±5.04*#
Emotional function 55.94±5.46 62±5.67* 55.47±5.41 66±5.24*#
Cognitive function 59.43±5.34 66±5.48* 59.54±5.03 72±4.31*#
Social function 45.25±4.52 54±3.27* 45.74±4.61 60±3.57*#
Health condition 50.21±2.67 57±3.31* 50.87±2.98 65±3.49*#
Table 3 The functional areas and total health status scores of the QLQ-C30 questionnaire before and after treatment in both groups (x ± s)
Symptom Control group(n=42) Experimental geoup(n=42)
Before treatment After treatment Before treatment After treatment
Fatigue 45.68±3.24 41.35±2.96* 44.98±3.45 35.42±3.09*#
Nausea and vomiting 35.54±4.57 28.34±4.36* 35.07±3.94 22.41±4.13*#
Pain 48.57±3.46 42.65±3.16* 48.42±3.54 31.54±3.47*#
Shortness of breath 35.36±4.61 30.74±4.34* 35.43±3.97 22.64±4.26*#
Insomnia 44.67±5.46 35.47±5.24* 44.76±5.78 26.34±5.21*#
Loss of appetite 43.84±6.42 36.66±5.14* 44.05±2.86 30.78±3.95*#
Constipation 17.54±2.05 13.54±2.31* 17.68±2.18 10.24±2.24*#
Diarrhea 16.12±0.14 14.94±0.11* 16.32±0.16 10.41±0.13*#
Table 4 QLQ-C30 questionnaire symptom score before and after treatment in two groups of patients
1.   Bray F, Ferlay J, Soer JR, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality wordwide for 36cancers in 185 countries. CA Cancer J Clin 2018, 68(6): 394-424.
2.   Barthelme S, Gedert H, Boitze C, et al. Solitary fibroustumors/hemangiopericytomas with different vaiants of the NAB2-STAT6 gene fusion is characterized by specific histomorphology and distinct clinicopathologicalfeatureas. Am J Pathol 2014,184(4): 1209-1218.
3.   Liu Baodong, Ye Xin, Fan Weijun, et al. Image-guided radiofrequency ablation for the treatment of lung cancer experts (2018 edition). Chin J Lung Cancer 2018, 21(2): 76-88, 86.
4.   Dupuy DE, Zagoria RJ, Akerley W, et al. Percutaneousradiofrequency ablation of malignancies in the lung. AJR Am J Roentgenol 2000, 174(1): S7-59.
5.   Ng CS, Gonzalez-Rivas D, Damico TA, et al. Uniportal VATS-a new era in lung cancer surgery. J THorac Dis 2015, 7(8): 1489-1491.
6.   Li XQ, Zhang Y, Huang DB, et al. Value of C-arm computed tomography in radiofrequency ablation of small lung lesions. Genetics Molecular Res 2014, 13(3): 6027-6036.
7.   Kato K, Abe H, Ika M, et al. C-Arm cone beam computed tomography guidance for radiofrequency ablation in hepatocellular carcinoma. Oncol 2017, 92(3): 142-152.
8.   Xie F, Zheng X, Xiao B, et al. Navigation bronchoscopy-guided radiofrequency ablation for nonsurgical peripheral pulmonary tumors. Respiration 2017, 94(3): 293-298.
9.   Wan CH, Chen MQ, Zhang CZ, et al. Review of EORTC QLQ-C30 Chinese version of cancer patient quality of life measurement scale. J Practical Oncol. Review of EORTC QLQ-C30 Chinese version of cancer patient quality of life measurement scale. J Practical Oncol 2005, (4).
10.   Liu BD, Li YH, Hu M, et al. Preliminary clinical application of radiofrequency ablation in the local progression of EGFR-TKIs in the treatment of non-small cell lung cancer. Chin J Lung Cancer 2016,19(12): 859-863.
11.   Zheng QC, Zhang QH, Zhai YZ, et al. Clinical observation of CT-guided radiofrequency ablation combined with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer. Chin Medl innovation 2015,16:78-80.
12.   Chen XL, Fu JG, Zhang M, et al. Effects of radiofrequency ablation combined with targeted therapy on quality of life in patients with non-small cell lung cancer. J ClinPulmon Med 2015,20(3):398-401.
[1] Fan-Ming Kong, Yang Yao, Ren-Fen Deng, Tian-Qi Chen, Dong-Ying Liao, Xiao-Jiang Li, Ying-Jie Jia. Xiaoyan decoction inhibits tumor growth and improves the immunity of mouse with A549 lung carcinoma xenograft[J]. 93TMR Cancer, 2019, 2(4): 227-232.
[2] Liu Pu, Wei-Hao Chen, Kun-Ji Wu, Ji-Huan Lin, Cheng-Lu Li, Shu-Lian Chen, Lu-Xi Cao, Shi-Qi Wang, Shu-Jun Lin, Yi-Min Zhang, Ming-Min Zhu. Immunoregulation of KangAi injection combined with chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis[J]. 93TMR Cancer, 2019, 2(2): 170-180.
[3] Yan-Juan Zhu, Zou Ying, Hui-Hui Chen, Xiao-Feng Jiang, Xian Chen, Li-Rong Liu, Yi-Hong Liu, Hai-Bo Zhang. Effect of Chinese medicine prescriptions of warming-Yang or cooling-heat combined with Gefitinib on H1650 cell line[J]. 93TMR Cancer, 2018, 1(1): 22-28.